Bladder Urothelial Carcinoma Clinical Trial
Official title:
An Open Label, Randomized Control Study of Probiotics Administration in the Immunotherapy of Urothelial Bladder Carcinoma
A study of the efficacy and safety of probiotics in immunotherapy of urothelial carcinoma.
To evaluate the progression free survival of intestinal probiotics in immunotherapy for urothelial carcinoma. Changes in fecal flora abundance before and after treatment were assessed to identify subjects most likely to benefit from enteric probiotics treatment. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT03039413 -
Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy
|
Early Phase 1 | |
| Active, not recruiting |
NCT03601455 -
Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer
|
Phase 2 | |
| Completed |
NCT02989064 -
MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers
|
Phase 1 | |
| Terminated |
NCT00072137 -
Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy
|
Phase 1 | |
| Withdrawn |
NCT05564416 -
Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial
|
Phase 2 | |
| Recruiting |
NCT04570410 -
Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06167356 -
Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.
|
||
| Terminated |
NCT05052372 -
Biomarker Research Study for Patients With FGFR-Mutant Bladder Cancer Receiving Erdafitinib
|
||
| Terminated |
NCT03266900 -
A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival
|
Early Phase 1 | |
| Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
| Active, not recruiting |
NCT03473730 -
Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer
|
Early Phase 1 | |
| Active, not recruiting |
NCT03138824 -
Storz Professional Image Enhancement System Versus White Light Imaging Assisted TURBT for Treatment of NMIBC
|
N/A | |
| Recruiting |
NCT05788484 -
A Study of CDX-585 in Patients With Advanced Malignancies
|
Phase 1 | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04216290 -
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes (The INSPIRE Study)
|
Phase 2 | |
| Recruiting |
NCT06416319 -
Preoperative Physical Activity Improvement With the Use of Activity Trackers Before Radical Cystectomy (PreAct)
|
N/A | |
| Active, not recruiting |
NCT03775265 -
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT06263153 -
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
|
Phase 2 | |
| Completed |
NCT00238420 -
Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02496208 -
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors
|
Phase 1 |